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drug-induced Brugada syndrome (BS).Background Patients with BS <12 years of age with a spontaneous type I electrocardiogram have a higher risk of arrhythmic
events. Data on drug-induced BS in patients <12 years of age are lacking.Methods Among 505 patients with ajmaline-induced BS, subjects 12 years of age at the time of diagnosis were considered
as children and eligible for this study.Results Forty children (60% male; age 8  2.8 years) were included. Twenty-four children (60%) had a family history of
sudden death. Two (5%) had a previous episode of aborted sudden death, and 8 (20%) had syncope. Children
experienced more frequent episodes of sinus node dysfunction (SND) compared with older subjects (7.5% vs. 1.5%;
p ¼ 0.04) and had a comparable incidence of atrial tachyarrhythmias. Children more frequently experienced
episodes of ajmaline-induced sustained ventricular arrhythmias (VAs) compared with older patients (10.0% vs.
1.3%; p ¼ 0.005). Twelve children (30%) received an implantable cardioverter-deﬁbrillator (ICD). After a mean
follow-up time of 83  51 months, none of the children died suddenly. Spontaneous sustained VAs were
documented in 1 child (2%). Among children with ICD, 1 (8%) experienced an appropriate shock, 4 (33%) had
inappropriate ICD shocks, and 4 (33%) experienced device-related complications.Conclusions Drug-induced BS is associated with atrial arrhythmias and SND. Children are at higher risk of ajmaline-induced VAs.
The rate of device-related complications, leading to lead replacement or inappropriate shocks, is considerable and
even higher than with appropriate interventions. Based on these ﬁndings, the optimal management of BS in
childhood should remain individualized, taking into consideration the patient’s clinical history and family’s
wishes. (J Am Coll Cardiol 2014;63:2272–9) ª 2014 by the American College of Cardiology FoundationBrugada syndrome (BS) is an inheritable syndrome charac-
terized by coved-type ST-segment elevation in the right
precordial leads (V1 to V3) and increased risk of sudden death
(SD) in the absence of structural heart disease (1). Pharma-
cological challenge with ajmaline, a potent sodium channel
blocker with a short half-life, is the recommended test to
unmask the diagnostic Brugada electrocardiogram (ECG)
pattern in patients with suspected BS and nondiagnostic
ECG (2). Although in the initial description of a series of 8
patients with BS, 3 individuals were children (including thet Centre, yPediatric Department, and zCardiac
B, Brussels, Belgium. Prof. Brugada reports
. Jude Medical, and Biotronik. All other authors
nships relevant to the contents of this paper to
2013; revised manuscript received February 15,ﬁrst and the second patients ever diagnosed with the syn-
drome), subsequent studies revealed that prevalence of BS in
the pediatric population is extremely low (0.0098%)
compared with the adult population (0.14% to 0.7%) (3,4).
Moreover, the mean age of patients presenting with either
symptomatic or asymptomatic BS is reportedly in the fourth
or ﬁfth decade (5). Clinical aspects and prognosis of either
spontaneous or drug-induced BS have been previously
described in individuals <16 years of age, and, as in adults, a
higher risk of arrhythmic events has been found
in symptomatic patients and in those displaying a sponta-
neous type I ECG (6). However, speciﬁc data on the clini-
cal characteristics and prognosis of drug-induced BS in
patients <12 years of age are lacking. In addition,
no generally accepted or evidence-based guidelines are
available for the speciﬁc therapeutic management of BS
in this particular population and for the family screening of
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2273asymptomatic pediatric relatives of adult patients with BS
and normal baseline ECG.
The purpose of the present study was to analyze our single-
center experience of BS in children gathered over the last 20
years (since the ﬁrst description of the syndrome). Particularly,
our goal was to assess the clinical features, the based-device
management, and the long-term follow-up of drug-induced
BS in subjects 12 years of age at the time of diagnosis.study
ICD = implantable
cardioverter-deﬁbrillator
PVS = programmed
ventricular stimulation
SD = sudden death
SND = sinus node
dysfunction
VA = ventricular arrhythmia
VF = ventricular ﬁbrillation
VT = ventricular tachycardiaMethods
Study population. Since 1992, all consecutive patients
diagnosed with BS by using an ajmaline challenge have been
included in a registry and followed up in a prospective
fashion. The ethics committee of the UZ Brussel-VUB
approved the study protocol. A total of 505 patients with
an ajmaline-induced diagnosis of BS were included in the
registry from 1992 to 2013. In this group, 40 children were
identiﬁed. Their data were used in the present study and
compared with those of adult patients. Patients were
considered as children if they were 12 years of age at the
time of diagnosis (7). Physical examination, medical history,
and baseline ECG were obtained, and underlying structural
cardiac abnormalities were excluded in all patients. The
recommendations of the Brugada consensus reports were
used for establishing the diagnosis and for determination of
candidacy for implantable cardioverter-deﬁbrillator (ICD)
therapy (8). Accordingly, ECGs were classiﬁed as Brugada
coved-type (type I) or saddleback (type II) or normal. An
ECG was considered diagnostic of BS if a coved-type ST-
segment elevation 2 mm was documented in 1 lead from
V1 to V3 in the presence or absence of a sodium channel
blocker agent. Only patients with nondiagnostic baseline
ECGs (normal ECG or Brugada type II ECG) were
considered eligible for this study. All baseline and drug-
induced 12-lead ECGs were recorded at a paper speed of
25 mm/s and amplitude of 10 mm/mV, with the right
precordial leads positioned at the sternal margin of the third
and fourth intercostal space. All ECGs were analyzed by 2
independent experienced electrophysiologists; in case
of disagreement, a third physician was consulted. Electro-
physiological study (EPS) was performed at the inves-
tigators’ preference in asymptomatic patients with BS to
assess risk stratiﬁcation. A maximum of 3 ventricular
extrastimuli with a minimum coupling interval of 200 ms
was delivered from 1 ventricular site unless ventricular
ﬁbrillation (VF) or sustained ventricular tachycardia (VT)
was induced.
Diagnosis of sinus node dysfunction (SND) was based on
the correlation of symptoms with the presence of docu-
mented arrhythmias such as sinus bradycardia, sinus arrest,
paroxysmal supraventricular tachycardia alternating with
periods of bradycardia, or even asystole. Chronotropic
incompetence, characterized by an impaired heart rate
response to exercise, was considered as an additional mani-
festation of SND and was deﬁned as failure to achieve 85%of the age-predicted maximum
heart rate (9). Conventional 24-
or 48-h Holter monitoring was
performed in any case of sus-
pected SND. Moreover, elec-
trophysiological evaluation of
SND was performed in all pa-
tients who underwent an EPS.
Electrophysiological evaluation of
SND included measurement of
sinus node recovery time (SNRT),
corrected SNRT (CSNRT ¼
SNRT  sinus cycle length),
SNRT/sinus cycle length 
100% (%SNRT), and sinoatrial
conduction time estimated by
using the method described
by Narula et al. (10).
Ajmaline challenge. Ajmaline
(1 mg/kg) was administered
intravenously over a 5-min period to unmask the diagnostic
ECG pattern of BS in case of nondiagnostic basal ECG.
Drug administration was usually performed under drug
sedation by injection of a single bolus of propofol in patients
<5 years of age. The test was considered positive for BS only
if coved-type I ECG was documented in 1 right precordial
lead (V1 to V3). Ajmaline infusion was discontinued before
reaching the target dose if QRS prolongation exceeded 30%
compared with the baseline interval, when frequent prema-
ture ventricular beats or type 1 Brugada ECG occurred,
or in the case of development of high-degree AV block.
All ECGs were analyzed before and after ajmaline admin-
istration. Heart rate, PR interval, QRS duration, and QTc
interval (determined by using Bazett’s formula) were
measured in milliseconds. Maximal ST-segment elevation
was measured at the J point in the right precordial leads
(V1 to V3), and the analysis of ST-segment elevation was
performed in lead V1 and V2 at 40 ms from the J point.
ECG measurements were repeated after ajmaline challenge.
Ajmaline-induced sustained ventricular arrhythmia (VA)
was deﬁned as the occurrence of VF or sustained VT (lasting
at least 30 s, accompanied by syncope or requiring inter-
vention for termination).
Genetic analysis. Genetic testing with sequence analysis of
SCN5A was recommended for all children who had a diag-
nosis of BS. Genomic DNA was extracted from peripheral
blood leukocytes by using standard protocols. If no mutation
was identiﬁed, sequence analysis of other genes (e.g.,
CACNA1C, SCN1B, KCNE3, SCN3B) was considered.
Mutation-speciﬁc genetic testing was recommended for
family members and appropriate relatives, after identiﬁca-
tion of the BS-causative mutation in an index case. In this
study, children having undergone genetic testing were only
screened for mutation in the SCN5A gene.
ICD implantation. The decision to place epicardial versus
endocardial ICD leads and the appropriate location for the
Table 1
Clinical Characteristics and ECG Parameters of Group I
(12 Years of Age) and Group II (>12 Years of Age)
Group I
(n ¼ 40)
Group II
(n ¼ 465) p Value
Clinical characteristics
Male 24 (60) 271 (58) 0.87
Family history of SCD 24 (60) 218 (47) 0.13
Clinical presentation
Asymptomatic 30 (75) 236 (51) 0.003
Syncope 8 (20) 123 (26) 0.37
Aborted SCD 2 (5) 16 (3.4) 0.61
History of atrial arrhythmias 3 (7.5) 33 (7) 0.92
Documented SND 3 (7.5) 7 (1.5) 0.04
ECG baseline parameters
PR interval, ms 140  28 173  32 <0.001
QRS duration, ms 92  15 98  20 0.06
QTc interval, ms 404  37 409  26 0.37
Maximal ST-segment
elevation, mm
0.52  0.25 0.58  0.18 0.73
Brugada type II ECG 3 (7.5) 63 (13.5) 0.27
Incomplete RBBB 1 (2.5) 23 (5) 0.48
First-degree AV block 1 (2.5) 62 (13) 0.05
Values are n (%) or mean  SD.
AV ¼ atrioventricular; ECG ¼ electrocardiogram; RBBB ¼ right bundle branch block; SCD ¼
sudden cardiac death; SND = sinus node dysfunction.
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and activity level. The choice between single- and dual-
chamber devices was driven by the presence of previous
episodes of supraventricular arrhythmias or the evidence of
SND. The device was usually programmed to treat ven-
tricular rates >200 beats/min, and a VT-monitoring zone
was occasionally added. However, these settings were
adjusted on the basis of the patient’s clinical history and to
avoid inappropriate ICD therapies during follow-up.
Follow-up. Follow-up of patients consisted of physical
examination and ECGs performed at least every 6 months.
Clinical data were regularly collected. Patients with ICDs
underwent scheduled follow-up of the device at 1 and
3 months and thereafter every 6 months. Beginning in 2006,
devices with home-monitoring capabilities were implanted
either de novo or at battery change, in case of previous
implantation, in all patients 12 years of age.
Statistical analysis. Data are presented as mean  SD or as
absolute values and percentages where appropriate. The chi-
square test and the Fisher exact test were used to compare
categorical variables. Continuous variables between the 2
groups were analyzed by using the unpaired or paired Stu-
dent t test as appropriate. A p value <0.05 was considered
statistically signiﬁcant. A z-score was calculated by using
mean  SD values of the general population as reference
values. Statistical analyses were conducted by using SPSS
version 21 (IBM SPSS Statistics, IBM Corporation,
Armonk, New York).Results
Baseline characteristics. Among all patients with drug-
induced BS included in our database, 40 individuals (8%)
were 12 years of age (group I) and 465 (92%) were >12
years of age (group II) at the time of diagnosis. Baseline
clinical characteristics and ECG parameters of the study
population are shown in Table 1.
Patients in group I (60% male; mean age 8  2.8 years;
range 1 to 12 years) belonged to 32 different families. Family
history of SD was present in 24 children (60%). There were
2 children (5%), aged 6 and 11 years, who presented with
a previous episode of aborted SD due to VF. Aborted SD
was the ﬁrst clinical manifestation of the syndrome in both
patients. No signiﬁcant differences were found in the sex,
family history of SD, or previous episodes of aborted SD
between groups I and II.
Indications for ajmaline challenge were: family screening
in 30 asymptomatic children (75%), syncope in 3 family
members (8%), syncope in 1 child (2%) with Brugada type II
ECG, syncope and family history of SD in 2 individuals
(5%), syncope and documented atrial arrhythmias together
with signs of SND in 2 subjects (5%), and aborted SD in
the remaining 2 children (5%).
Eight children (20%) presented with syncope, and 30
patients (75%) were asymptomatic family members. No
signiﬁcant difference was found in the history of syncopebetween group I and group II. Children presented more
frequently as asymptomatic family members compared with
older patients (75% vs. 51%; p ¼ 0.003). Mean age at the
ﬁrst symptom was 6  5 years. Syncopal episodes occurred
at rest in 7 children and during exercise in 1 child. In 2 cases
(25%), syncope was associated with fever. No signiﬁcant
difference was found in the sex of symptomatic patients
between the 2 groups (male 70% vs. 62%; p ¼ 0.7). Among
children with family history of SD, 4 patients (17%) pre-
sented with syncope before the diagnosis of BS, and none of
them had had a previous episode of aborted SD. However,
among children with no family history of SD, 5 (31%)
presented with syncope or aborted SD. A family history of
SD in children was not signiﬁcantly associated with the
presence of symptoms before the diagnosis of BS (17% vs.
31%; p ¼ 0.44).
Two children (5%) had previous documented episodes
of atrial ﬁbrillation (AF) and 1 child (2.5%) had atrial
ﬂutter. Three children (7.5%) presented with SND. History
of sustained atrial arrhythmias (AF or atrial ﬂutter) was
comparable between groups (7.5% vs. 7.1%; p ¼ 0.92).
Children presented more frequently with signs of SND
compared with individuals >12 years of age (7.5% vs. 1.5%;
p ¼ 0.04). Furthermore, a history of AF and SND was
more frequently present in symptomatic children compared
with asymptomatic children (30% vs. 0%; p ¼ 0.01).
Before the diagnosis of BS, no episode of second- or third-
degree AV block was documented in any patient 12 years
of age.
Thirty-four children (85%) presented with a normal
baseline ECG. Three patients (7.5%) presented with
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branch block on baseline ECG, 1 child (2%) presented with
incomplete right bundle branch block, and another child
(2%) presented with complete right bundle branch block.
Patients 12 years of age more frequently had a normal
baseline ECG compared with older individuals (85% vs.
52%; p < 0.01). No signiﬁcant differences were found in the
baseline QRS duration or QTc interval. Conversely, baseline
PR interval was signiﬁcantly longer in patients >12 years
of age compared with younger subjects (173  32 ms vs.
140  28 ms; p < 0.01). One child (2%) presented with a
baseline PR interval >200 ms. A statistically signiﬁcant
difference was found in the percentage of patients with
baseline ﬁrst-degree AV block (>200 ms) between groups I
and II (2% vs. 13%; p ¼ 0.05).
An EPS was performed for risk stratiﬁcation purposes or
suspected SND in 24 children (60%). The mean HV in-
terval of these patients was 40.4  4.2 ms. Sustained VAs
were induced, during programmed ventricular stimulation
(PVS), in 2 children (8%). Rate of episodes of inducible
sustained VAs during PVS was higher in group II, although
no statistically signiﬁcant difference was found between the
2 groups (8% vs. 24%; p ¼ 0.08). Moreover, AF was easily
inducted during incremental atrial pacing in 2 children (5%).
A total of 19 genetic tests (47%) were obtained, and 4 (21%)
had positive results for the following mutations in the
SCN5A gene: (c.[3695G>A]þ[¼] (p.R1232Q), (c.[4813þ
6_4819þ9dupGGGT]þ[¼], (c.[2632C>T]þ[¼] (p.[R878C]
þ[¼]), (c.[2989G>A]þ[¼] (p.A997T).
Ajmaline challenge. From 1992 to 2013, a total of 169
individuals 12 years of age underwent an ajmaline chal-
lenge for suspected BS. Among them, ajmaline challenge
revealed a Brugada ECG type 1 in 40 children (24%). ECG
parameters before and after ajmaline administration are
shown in Table 2. After infusion of ajmaline, the PR in-
terval, QRS duration, and QTc interval increased in all
patients, with no signiﬁcant differences between the 2
groups. During ajmaline challenge, 3 children (7%) experi-
enced an episode of VF requiring external deﬁbrillation for
termination, and 1 child (3%) had a polymorphic VT
terminated by a high dose of isoproterenol infusion (Fig. 1).
Of note, ajmaline-induced sustained VAs were observed
more frequently in children compared with older patients
(10% vs. 1.3%; p ¼ 0.005). None of them had anyTable 2 Results of Ajmaline Challenge Test
Group I (n ¼ 40)
Baseline After Ajmaline p Value*
PR, ms 140  28 181  38 <0.01
QRS, ms 92  15 123  36 0.04
QTc V1, ms 400  28 452  78 0.38
QTc V2, ms 409  26 454  72 <0.01
Values are mean  SD. *P value in the paired t test for intragroup comparisons of ECG parameters b
increment in ECG parameters after the pharmacological test.
Abbreviations as in Table 1.nonsustained VA before the sustained VA initiation, and no
patient experienced any VA refractory to the ﬁrst shock.
Moreover, sustained VAs during ajmaline occurred more
frequently in symptomatic children compared with asymp-
tomatic subjects (30% vs. 3.3%; p ¼ 0.04). No child had a
prolongation of the HV interval after ajmaline administra-
tion to >100 ms. Furthermore, no advanced AV block was
observed during ajmaline challenge.
ICD implantation. Twelve children (30%) considered at
high risk for the development of VAs underwent ICD
implantation. Indications for ICD placement were: syncope
in 6 patients, aborted SD in 2 subjects, sustained VA
during ajmaline administration in 1 asymptomatic family
member, and syncope and ajmaline-induced sustained VA
in the remaining 3 children. Nine patients (75%) received a
single-chamber device, and 3 children (25%) underwent a
dual-chamber ICD implantation. Eleven children (92%)
underwent an abdominal implantation, and 8 patients
(67%) received an epicardial lead implantation. After ICD
implantation, 2 children (17%) experienced a device-related
early complication: an episode of pericarditis that occurred
1 month after epicardial lead placement and a dislocation of
the abdominal generator that led to revision of the device
1 week after implantation.
Long-term follow-up. After a mean follow-up time of
83  51 months, none of the children with ajmaline-
induced BS died suddenly (Table 3). One child (2%)
had spontaneous sustained VAs. Moreover, a previously
asymptomatic patient had a syncopal episode 3 years after
the diagnosis and underwent an ICD implantation. Another
child experienced 2 syncopal events, which were diagnosed
as neurally mediated syncope. One child (2.5%) developed
AF 2 years after being diagnosed with BS. Among children
who had undergone an ICD implantation, 1 patient (8%)
experienced an episode of appropriate shock due to VF.
Furthermore, 4 children with ICD (33%) had inappropriate
ICD shocks due to episodes of supraventricular tachycardia,
consisting of AF in 2 cases and sinus tachycardia in 1 child,
and noise on ventricular channel after lead fracture in
another child.
During follow-up, 4 children (33%) experienced device-
related complications: fracture of ventricular lead in 2
patients that led to replacement of the electrode, lead dislo-
cation in 1 child that led to revision of the device, and deviceGroup II (n ¼ 465)
p ValueyBaseline After Ajmaline p Value*
171  32 209  40 <0.01 0.55
98  20 127  28 <0.01 0.96
396  40 460  61 <0.01 0.31
405  37 459  45 <0.01 0.43
efore and after the pharmacological test. yp value in the t test for intergroup comparisons of the
Figure 1 Episode of Sustained Polymorphic VT During Ajmaline Challenge in a 7-Year-Old Boy Presenting With Syncope and Signs of SND
(A) Holter monitoring showing sinus pause. (B) Baseline electrocardiogram (ECG). (C) ECG during ajmaline challenge (dose of 0.7 mg/kg). (D) Appearance of Brugada type 1
ECG at an ajmaline dose of 1 mg/kg. (E) ECG 1 min after ajmaline challenge. T-wave alternans can be seen in V1 and V2 leads (arrows). (F) Episode of polymorphic ventricular
tachycardia (VT) 2 min after ajmaline challenge. SND ¼ sinus node dysfunction.
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the device. Moreover, 1 child, who had experienced multiple
inappropriate ICD shocks for drug-resistant AF with rapid
ventricular response, underwent pulmonary vein isolation by
means of cryoballoon ablation. Although nonsustained runs
of AF were documented, the patient remained free from
ICD shocks without antiarrhythmic therapy 12 months after
the procedure. None of the children who experienced VAs
during ajmaline challenge had further VA events during
follow-up.Table 3
Long-Term Follow-Up of Children With
Brugada Syndrome
SCD 0
Syncope 2 (5%)
Documented life-threatening arrhythmias 1 (2%)*
Newly diagnosed AF 1 (2%)
Appropriate ICD interventions 1 (8%)*
Inappropriate ICD interventions 4 (33%)
Device-related complications 4 (33%)
Pulmonary vein isolation 1 (8%)
Values are n or n (%). *Same patient.
ICD ¼ implantable-cardioverter deﬁbrillator; other abbreviations as in Table 1.Discussion
To our knowledge, this is the largest series of children with
drug-induced BS. Moreover, this is the ﬁrst report
addressing the clinical features and the long-term follow-up
of BS in this speciﬁc category of BS patients.
Clinical presentation of BS in childhood. Although BS is
thought to be an inherited primary arrhythmia syndrome
with autosomal dominant inheritance, it is rarely diagnosed
in children. In fact, ECG penetrance in SCN5A mutation
carriers has been shown to be considerably lower in children
than in adults (17% vs. 100%) (11). Moreover, genetic and
clinical heterogeneity of BS can lead some individuals with
syncopal episodes to exhibit the Brugada type I ECG as well
as a positive response to sodium channel blocker drugs in an
age-dependent manner (12). In addition, in a single-family
study of a SCN5A mutation causing both BS and long-
QT syndrome, QT prolongation was recognized from
birth onward, whereas ST-segment elevation became
apparent only after 5 years of age (13). All these data suggest
that although patients are born with the pathological mu-
tation, both the symptoms and the ECG phenotype in the
large majority of cases do not manifest during childhood.
Age-dependent clinical and ECG manifestation of BS can
JACC Vol. 63, No. 21, 2014 Conte et al.
June 3, 2014:2272–9 Drug-Induced Brugada Syndrome in Children
2277be inﬂuenced by multiple factors, including hormonal,
autonomic, and genetic substrates. In particular, testosterone
may play a role as a potential hormone responsible for the
age-dependent manifestation of BS phenotype, as suggested
by the disappearance of Brugada type I ECG after surgical
castration for prostate cancer (14). However, although
infrequent, BS can present with an extremely severe mani-
festation in early childhood and can be a cause of unex-
plained sudden cardiac death in children (15). In 2007,
Probst et al. (6) described a series of 30 patients <16 years of
age affected by BS, and 13 of them presented with
drug-induced type I ECG. Among the drug-induced BS
patients, only 1 subject was symptomatic, and no male
predominance was observed in the total cohort or in those
with symptoms. In our study, 24% of children who under-
went an ajmaline challenge for suspected BS had a positive
response to the pharmacological test; they represented only
8% of all patients diagnosed with ajmaline-induced BS in
the last 20 years, suggesting that response to ajmaline can
also be age-dependent. Furthermore, 25% of our study
population presented with symptoms (syncope or aborted
SD). Although only subjects 12 years of age were
considered as “children” to avoid any hormonal inﬂuence in
the clinical and ECG manifestation of the syndrome, 60% of
children and 70% of symptomatic children were male.
Moreover, although 2 patients with previous aborted SD
were both female, no signiﬁcant difference was found in the
sex of symptomatic patients between children and older
patients. These data may suggest that testosterone or other
hormonal factors could be involved in determining male
predominance of BS in symptomatic children as well. Age-
dependent clinical and ECG manifestation of BS in children
should be investigated with further studies.
Supraventricular arrhythmias and SND are common
arrhythmic disorders in adults with BS (16,17). In the
present study, similar to the adult population, sustained
atrial arrhythmias (e.g., AF, atrial ﬂutter) were not uncom-
mon ﬁndings, occurring in 7.5% of children with BS. Of
note, children with BS more frequently had SND compared
with older subjects. Moreover, symptomatic children pre-
sented more frequently with previous episodes of atrial
arrhythmias and signs of SND compared with asymptomatic
subjects. These data suggest that in children with SND or
documented atrial arrhythmias and normal basal ECG, BS
should be excluded, particularly if the child presents with
syncope.
It has been shown that age exerts a signiﬁcant inﬂuence
on the duration of PR interval in normal subjects. In fact, as
the child grows older, the average PR interval lengthens
progressively from an average value of 0.114 s at 1 year of
age to 0.15 s at 13 years of age (18). In our study, the baseline
PR interval was signiﬁcantly shorter in patients <12 years
of age compared with older subjects, suggesting that age
might also exert an inﬂuence on the duration of PR interval
in patients with BS. Interestingly, the baseline PR interval of
our study population was longer if compared with theexpected PR interval for the same age group (mean z-score:
7.6  16.4) (19). Moreover, in our study, 1 child (2.5%)
presented with a PR interval >200 ms.
Although children with BS present less frequently with
ﬁrst-degree AV block compared with older patients, inci-
dence of ﬁrst-degree AV block seems to be higher in chil-
dren with BS than in the general pediatric population (2.5%
vs. 0.02%) (20). Because BS is a channelopathy caused by a
loss of function of the sodium channel, it would not be
surprising that conduction defects, including ﬁrst-degree
AV block, could coexist with the typical ST-segment
elevation, regardless of the age of the patient (21). Hor-
monal inﬂuence may play a role in determining development
of conduction defects in BS patients after puberty. Further
speciﬁc studies are needed to conﬁrm these ﬁndings.
Ajmaline challenge. Ajmaline challenge is an established
tool to unmask the diagnostic Brugada ECG pattern in
patients with suspected BS and nondiagnostic ECG (2).
However, its value in unmasking BS and its safety in chil-
dren have not been systematically investigated. Veltmann
et al. (22) reported a positive response to ajmaline in 262
(39%) of 677 patients with a normal ECG and suspected
BS. The mean age of this subgroup of patients was 44 
15 years, and 62% were male. Conversely, Rolf et al. (23)
reported 23% of adult patients (mean age 42 years) with
Brugada type I ECG after ajmaline challenge. In our study,
BS was diagnosed after ajmaline challenge in 24% of chil-
dren with suspected BS. Ajmaline is considered the best
agent for unmasking BS, both because of the drug’s kinetics
and its strength of rate-dependent sodium channel–blocking
effects. Moreover, its short half-life and brief duration of
electrophysiological effects offer a clinical advantage
compared with other antiarrhythmic drugs. Unfortunately,
ajmaline is not available worldwide. Other drugs, such as
ﬂecainide or procainamide, can be used to reveal the Bru-
gada type I ECG in these cases. However, ﬂecainide has
been shown to have a lower sensitivity to unmask the
diagnostic Brugada ECG compared with ajmaline (2). A
greater inhibition of Ito may render it less effective. In
addition, ﬂecainide needs longer monitoring of the patients
due to its prolonged pharmacological effect. Moreover,
procainamide, a class IA antiarrhythmic drug, displays a
more rapid dissociation from the sodium channel and
consequently a lower level of use-dependent sodium channel
blockade.
In the study by Rolf et al. (23), occurrence of sustained
VAs was reported in 1.3% of patients who underwent
ajmaline challenge for suspected BS. All episodes of VAs
reported occurred in patients in whom drug administration
was not discontinued after the appearance of diagnostic
Brugada ECG changes. Conversely, Veltmann et al. (22)
reported an incidence of sustained VAs in 0.1% of pa-
tients. In a more speciﬁc BS population consisting of
patients <16 years of age, Probst et al. (6) found no
occurrence of adverse events during drug challenge. Con-
versely, in our study, ajmaline provoked sustained VAs in
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22784 children (10%), and 3 of them (75%) were symptomatic
for syncope. Importantly, children <12 years of age
exhibited a higher risk of experiencing an ajmaline-induced
VA compared with older patients (10.0% vs. 1.3%; p ¼
0.005). The absence of events during ajmaline testing in the
series by Probst et al. might be explained by the lower rate
of symptomatic children (8%) having undergone ajmaline
challenge compared with our study population (25%). Our
data conﬁrm the necessity, for this category of patients, of
performing ajmaline challenge in a safe environment with
life-support facilities available, especially when children
present with a history of syncope.
Device-based management. Twelve (30%) of our study
children were considered at high risk of arrhythmic events
and underwent ICD implantation. Although the manage-
ment of asymptomatic children with drug-induced BS is
straightforward, the device-based therapeutic management
of symptomatic children is challenging. Moreover, ICD
implantation in this particular set of patients is not without
potential problems, given the subjects’ very young age. It has
already been shown that the rate of lead-related problems in
pediatric patients is high: 23% of children with a pacing
device can, in fact, experience a lead failure (24). In our
study, during a mean follow-up of 83  51 months, 33% of
children experienced device-related complications. Impor-
tantly, lead-related problems can give rise to inappropriate
therapies with signiﬁcant impact on the quality of life of
children and relatives.
Long-term follow-up. All large registries including pa-
tients with BS and syncope reported that 6% to 19% of
patients experienced an arrhythmic event during a follow-up
of 24 to 39 months (5,25,26). In adults with BS, clinical
symptoms such as syncope or aborted SD or spontaneous
Brugada type I ECG are associated with a higher risk of
SD during the follow-up. Probst et al. (6) reported that 2
(7%) of 30 patients experienced documented VAs during the
follow-up that led to appropriate shocks. Both patients were
symptomatic, with syncope and manifestation of a sponta-
neous type I ECG. Furthermore, inappropriate ICD inter-
vention was recorded in 1 patient (20%). In a previously
reported series, the incidence of inappropriate shocks was
only slightly lower than the incidence of appropriate shocks,
ranging from 17% to 23% for primary prevention and up
to 30% for secondary prevention. In our study, only 1 child
(2%) with drug-induced BS and syncope had a documented
sustained VA successfully terminated by appropriate ICD
intervention during follow-up. However, 4 children with
ICD (33%) had inappropriate shocks due to very rapid
supraventricular arrhythmias in 3 patients and lead fracture
in 1 child.
On the basis of these ﬁndings, the optimal management
of BS in childhood remains challenging and, due to the
considerable rate of inappropriate ICD interventions and
potential device-related complications, it should be always
individualized, taking into consideration patient’s age, clin-
ical history, and the family’s wishes. For asymptomatic BSchildren, a clinical follow-up with 12-lead ECG should be
performed every 6 months. In these patients, particular
attention should be paid after puberty to reveal potential
appearance of spontaneous Brugada type I ECG or symp-
toms. Moreover, because fever is an important trigger for
ventricular arrhythmias in BS, antipyretic therapy should
be promptly administered during any febrile episode, and
parents should bring the child to the hospital for clinical
evaluation, ECG, and monitoring of cardiac activity (6).
A hospital stay should be considered whether fever causes
Brugada type I ECG or appearance of VAs.
Although there is a psychological impact for the patient
and the family, family history of SD has not been shown to
be predictive of future arrhythmic events in adults with BS
and seems to be of no prognostic value in children (27).
Thus, asymptomatic children with a family history of SD do
not have an indication to implant an ICD or to undergo an
EPS for risk stratiﬁcation purposes. A clinical follow-up
with ECG should be performed every 6 months in these
cases.
Conversely, ICD therapy, although associated with sig-
niﬁcant morbidity, should always be considered to prevent
SD in children with BS who present with a syncopal
episode, if no other cause of the syncope is found (8). The
decision to perform an ICD implantation in this setting
should always be made after a careful evaluation of the
syncopal episode and the family’s wishes, and it should be
performed following the best implantation technique in
accordance with the patient’s age. For those patients with
limited symptoms at a young age in whom the family does
not want to adopt an active approach, quinidine therapy
might be considered as an alternative to prevent arrhythmic
death until the child grows sufﬁciently to safely undergo
ICD implantation (28). However, systematic studies on this
approach in children are lacking.
Study limitations. This was a single-center experience,
conducted in a population of patients with heterogeneous
clinical characteristics, and its analysis was retrospective.
Moreover, EPS with PVS as well as genetic testing was not
performed in all children. Finally, no drug challenge was
repeated.
Conclusions
Similarly to that seen in adult patients, drug-induced BS in
children is commonly associated with male sex, sustained
atrial arrhythmias, and SND. Children seem to be a category
of BS patients at higher risk of experiencing sustained VAs
during ajmaline challenge. Moreover, in children with ICD,
the rate of device-related problems, which can lead to
electrode replacement or inappropriate shocks, is consider-
able and even higher than appropriate ICD interventions.
On the basis of these ﬁndings, the optimal management of
drug-induced BS in childhood should always be individu-
alized, taking into consideration the patient’s clinical history
and the family’s wishes.
JACC Vol. 63, No. 21, 2014 Conte et al.
June 3, 2014:2272–9 Drug-Induced Brugada Syndrome in Children
2279Reprint requests and correspondence: Dr. Giulio Conte, Heart
Rhythm Management Centre, Cardiovascular Division, UZ
Brussel-VUB, Laarbeeklaan 101, 1090 Brussels, Belgium. E-mail:
giulioconte.cardio@gmail.com.
REFERENCES
1. Brugada P, Brugada J. Right bundle branch block, persistent ST
segment elevation and sudden cardiac death: a distinct clinical and
electrocardiographic syndrome. A multicenter report. J Am Coll
Cardiol 1992;20:1391–6.
2. Wolpert C, Echternach C, Veltmann C, et al. Intravenous drug
challenge using ﬂecainide and ajmaline in patients with Brugada syn-
drome. Heart Rhythm 2005;2:254–60.
3. Yamakawa Y, Ishikawa T, Uchino K, et al. Prevalence of right bundle-
branch block and right precordial ST-segment elevation (Brugada-type
electrocardiogram) in Japanese children. Circ J 2004;68:275–9.
4. Hermida JS, Lemoine JL, Aoun FB, Jarry G, Rey JL, Quiret JC.
Prevalence of the Brugada syndrome in an apparently healthy popula-
tion. Am J Cardiol 2000;86:91–4.
5. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Bru-
gada syndrome: insights for risk stratiﬁcation and management.
Circulation 2002;105:1342–7.
6. Probst V, Denjoy I, Meregalli P, et al. Clinical aspects and prognosis of
Brugada syndrome in children. Circulation 2007;115:2042–8.
7. Williams K, Thomson D, Seto I, et al., StaR Child Health Group. Age
groups for pediatric trials. Pediatrics 2012;129 Suppl 3:S153–60.
8. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome:
report of the Second Consensus Conference. Circulation 2005;111:
659–70.
9. Holden W, McAnulty JH, Rahimtoola SH. Characterization of heart
rate response to exercise in the sick sinus syndrome. Br Heart J 1978;
20:923–30.
10. Narula OS, Shantha N, Vasquez M, Towne WD, Linhart JW. A new
method for measurement of sinoatrial conduction time. Circulation
1978;58:706–14.
11. Schulze-Bahr E, Eckardt L, Breithardt G, et al. Sodium channel gene
(SCN5A) mutations in 44 index patients with Brugada syndrome:
different incidences in familial and sporadic disease. Hum Mutat 2003;
21:651–2.
12. Makita N, Sumitomo N, Watanabe I, Tsutsui H. Novel SCN5A
mutation (Q55X) associated with age-dependent expression of Brugada
syndrome presenting as neurally mediated syncope. Heart Rhythm
2007;4:516–9.
13. Beaufort-Krol GC, van den Berg MP, Wilde AA, et al. Developmental
aspects of long QT syndrome type 3 and Brugada syndrome on thebasis of a single SCN5A mutation in childhood. J Am Coll Cardiol
2005;46:331–7.
14. Matsuo K, Akahoshi M, Seto S, Yano K. Disappearance of the
Brugada-type electrocardiogram after surgical castration: a role for
testosterone and an explanation for the male preponderance. Pacing
Clin Electrophysiol 2003;26:1551–3.
15. Priori SG, Napolitano C, Giordano U, Collisani G, Memmi M.
Brugada syndrome and sudden cardiac death in children. Lancet 2000;
355:808–9.
16. Eckardt L, Kirchhof P, Loh P, et al. Brugada syndrome and supra-
ventricular tachyarrhythmias: a novel association? J Cardiovasc Elec-
trophysiol 2001;12:680–5.
17. Sumiyoshi M, Nakazato Y, Tokano T, et al. Sinus node dysfunction
concomitant with Brugada syndrome. Circ J 2005;69:946–50.
18. Alimurung MM, Massell BF. The normal P-R interval in infants and
children. Circulation 1956;13:257–62.
19. Davignon A, Rautaharju P, Boisselle E, Soumis F, Mégélas M,
Choquette A. Normal ECG standards for infants and children. Ped
Cardiol 1979/1980;1:123–31.
20. Chiu S, Wang J, WuM, et al. Cardiac conduction disturbance detected
in a pediatric population. J Pediatr 2008;152:85–9.
21. Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading
either to isolated cardiac conduction defect or Brugada syndrome in a
large French family. Circulation 2001;104:3081–6.
22. Veltmann C, Wolpert C, Sacher F, et al. Response to intravenous
ajmaline: a retrospective analysis of 677 ajmaline challenges. Europace
2009;11:1345–52.
23. Rolf S, Bruns HJ, Wichter T, et al. The ajmaline challenge in Brugada
syndrome: diagnostic impact, safety, and recommended protocol. Eur
Heart J 2003;24:1104–12.
24. Fortescue EB, Berul CI, Cecchin F, Walsh EP, Triedman JK,
Alexander ME. Patient, procedural and hardware factors associated
with pacemaker lead failure in pediatrics and congenital heart disease.
Heart Rhythm 2004;1:150–9.
25. Brugada J, Brugada R, Antzelevitch C, Towbin J, Nademanee K,
Brugada P. Long-term follow-up of individuals with the electrocar-
diographic pattern of right bundle-branch block and ST-segment
elevation in precordial leads V1 to V3. Circulation 2002;105:73–8.
26. Eckardt L, Probst V, Smits JP, et al. Long-term prognosis of in-
dividuals with right precordial ST-segment-elevation Brugada syn-
drome. Circulation 2005;111:257–63.
27. Sarkozy A, Sorgente A, Boussy T, et al. The value of a family history of
sudden death in patients with diagnostic type I Brugada ECG pattern.
Eur Heart J 2011;32:2153–60.
28. Hermida JS, Denjoy I, Clerc J, et al. Hydroquinidine therapy in Bru-
gada syndrome. J Am Coll Cardiol 2004;43:1853–60.Key Words: ajmaline - Brugada syndrome - children - sudden death.
